Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

Similar articles for PubMed (Select 23928724)

1.

[Update dyslipidemia].

Parhofer KG.

Internist (Berl). 2013 Sep;54(9):1089-103. doi: 10.1007/s00108-013-3335-3. German.

PMID:
23928724
2.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
3.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

4.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

5.

Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

Matikainen N, Taskinen MR.

Curr Cardiol Rep. 2012 Dec;14(6):721-31. doi: 10.1007/s11886-012-0309-3. Review.

PMID:
22941588
7.

Dyslipidemia: management using optimal lipid-lowering therapy.

Ito MK.

Ann Pharmacother. 2012 Oct;46(10):1368-81. doi: 10.1345/aph.1R127. Epub 2012 Oct 2. Review.

PMID:
23032652
8.

The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.

Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA.

Rev Cardiovasc Med. 2008 Fall;9(4):239-58. Review.

PMID:
19122582
9.

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators.

Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.

PMID:
21450578
10.

[Multimodal therapy of dyslipidemia].

Stahn A, Hanefeld M.

Clin Res Cardiol Suppl. 2011 May;6:10-6. Review. German.

PMID:
22528173
11.

Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.

Wanner C, Krane V.

Kidney Blood Press Res. 2011;34(4):209-17. doi: 10.1159/000326849. Epub 2011 Jun 21. Review.

PMID:
21691123
12.

Treatment of lipid disorders in obesity.

Tonstad S, Després JP.

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):1069-80. doi: 10.1586/erc.11.83. Review.

PMID:
21878051
13.

[Gastroenterological aspects of atherosclerosis].

Zvenigorodskaia LA, Samsonova NG, Efremov LI, Cherkashova EA, Lazebnik LB.

Eksp Klin Gastroenterol. 2011;(2):31-6. Russian.

PMID:
21560640
14.

Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.

Nakajima K.

Curr Clin Pharmacol. 2010 May;5(2):133-9. Review.

PMID:
20156152
15.

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2011 Jun;32(11):1345-61. doi: 10.1093/eurheartj/ehr112. Epub 2011 Apr 29. Review.

16.

Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS).

Drexel H, Chazelle F, Fauer C, Lautsch D, Gitt AK.

Wien Klin Wochenschr. 2011 Oct;123(19-20):611-7. doi: 10.1007/s00508-011-0057-1. Epub 2011 Sep 29.

PMID:
21947362
17.

[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].

Bajnok L.

Orv Hetil. 2014 Jan 12;155(2):62-8. doi: 10.1556/OH.2014.29797. Review. Hungarian.

PMID:
24389322
18.

'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.

Jacobson TA.

Int J Clin Pract. 2011 Jan;65(1):82-101. doi: 10.1111/j.1742-1241.2010.02547.x. Epub 2010 Nov 24. Review.

PMID:
21105969
19.

[Diabetic dyslipoproteinemia: beyond LDL].

Merkel M.

Dtsch Med Wochenschr. 2009 May;134(20):1067-73. doi: 10.1055/s-0029-1222571. Epub 2009 May 6. Review. German.

PMID:
19421932
20.

[Lipid management--treatment goal and strategy].

Koshiyama H.

Nihon Rinsho. 2006 Nov;64(11):2102-6. Review. Japanese.

PMID:
17087303
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk